MedTrace Logo

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

NCT01353040 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-05-07

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.

Conditions

  • Marburg Hemorrhagic Fever

Interventions

DRUG

AVI-6003

Single intravenous administration

DRUG

Placebo

Single intravenous administration

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Sarepta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Alison Heald, MD · Sarepta Therapeutics, Inc.

  • Apinya B Vutikullird, MD · West Coast Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01353040 on ClinicalTrials.gov